Antonio Carlos Bandeira has a total of 242 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development and Validation of ELISA for In Vitro Diagnosis of SARS-CoV-2 Infection

    by Larissa de Carvalho Medrado Vasconcelos, Leonardo Maia Leony, Ângelo Antônio Oliveira Silva, Aquiles Assunção Camelier, Antônio Carlos Bandeira, Isadora Cristina de Siqueira, Fred Luciano Neves Santos

    (1) Background: The ongoing global health threat posed by SARS-CoV-2 requires reliable and accessible diagnostic tools, especially in resource-limited settings where RT-qPCR may be impractical. This study describes the development and validation of two enzyme-linked immunosorbent assays (ELISA) designed to detect anti-SARS-CoV-2 IgG antibodies employing recombinant S1 and S2 spike protein subunits. (2) Methods: The assays were optimized and validated using serum samples from 354 RT-qPCR-confirmed hospitalized patients and 337 pre-pandemic blood donors. (3) Results: The S1-based ELISA achieved a 52.8% sensitivity and a specificity of 93.5%, with an area under the ROC curve (AUC) of 71.6%. In contrast, the S2-based ELISA demonstrated superior diagnostic performance, with a sensitivity of 63.7%, a specificity of 99.7%, and an AUC of 83.1%. Cross-reactivity analysis using sera from individuals with unrelated infectious diseases confirmed the high specificity of the S2-ELISA. Time-stratified analysis revealed that sensitivity increased with time, peaking between 15 and 21 days post-symptom onset. Compared to commercial serological assays, the S2-ELISA demonstrated comparable or improved performance, particularly in specificity and diagnostic odds ratio. (4) Conclusions: The S2-ELISA offers a robust, highly specific, and operationally simple tool for serological detection of SARS-CoV-2 infection. Its strong diagnostic performance and accessibility make it well-suited for implementation in diverse epidemiological settings, particularly where molecular testing is limited. The development of affordable, validated serological assays such as this is critical for strengthening surveillance, understanding transmission dynamics, and informing public health responses.

  • Open Access

    The next arbovirus epidemic in Latin America and beyond: A question of when, not if – Mayaro, Oropouche, Usutu or Disease X?

    by Salim Mattar, Yesica López, German Arrieta, Ameth Salim Mattar, Antonio Carlos Bandeira, Alberto Paniz-Mondolfi, Jan Felix Drexler, Alfonso J. Rodriguez-Morales


  • Zika virus: Infection of the central nervous system (CNS)

    by Antonio Carlos de Albuquerque Bandeira

  • Contributors

    by Samuel Abah, Daniel Aguilar Zapata, Kelvin Schmoeller Alberton, Joaquín Arzalluz Luque, Fernanda Barcelos Cardoso, Tatiana Barichello, Rebeca Benavente, Janis Blair, Karen C. Bloch, Poppy Cairney, et al.

  • Open Access

    Comprehensive Study of the IBMP ELISA IgA/IgM/IgG COVID-19 Kit for SARS-CoV-2 Antibody Detection

    by Sibelle Botogosque Mattar, Paola Alejandra Fiorani Celedon, Leonardo Maia Leony, Larissa de Carvalho Medrado Vasconcelos, Daniel Dias Sampaio, Fabricio Klerynton Marchini, Luis Gustavo Morello, Vanessa Hoysan Lin, Sandra Crestani, Aquiles Assunção Camelier, et al.

    COVID-19 laboratory diagnosis primarily relies on molecular tests, highly sensitive during early infection stages with high viral loads. As the disease progresses, sensitivity decreases, requiring antibody detection. Since the beginning of the pandemic, serological tests have been developed and made available in Brazil, but their diagnostic performance varies. This study evaluated the IBMP ELISA IgA/IgM/IgG COVID-19 kit performance in detecting SARS-CoV-2 antibodies. A total of 90 samples, including 64 from COVID-19 patients and 26 pre-pandemic donors, were assessed based on time post symptom onset (0–7, 8–14, and 15–21 days). The kit showed 61% sensitivity, 100% specificity, and 72% accuracy overall. Sensitivity varied with time, being 25%, 57%, and 96% for 0–7, 8–14, and 15–21 days, respectively. Similar variations were noted in other commercial tests. The Gold ELISA COVID-19 (IgG/IgM) had sensitivities of 31%, 71%, and 100%, while the Anti-SARS-CoV-2 NCP ELISA (IgG) and Anti-SARS-CoV-2 NCP ELISA (IgM) showed varying sensitivities. The IBMP ELISA kit displayed high diagnostic capability, especially as the disease progressed, complementing COVID-19 diagnosis. Reproducibility assessment revealed minimal systematic and analytical errors. In conclusion, the IBMP ELISA IgA/IgM/IgG COVID-19 kit is a robust tool for detecting anti-SARS-CoV-2 antibodies, increasing in efficacy over the disease course, and minimizing false negatives in RT-PCR COVID-19 diagnosis.


  • Open Access

    Assessing the performance of commercial serological tests for SARS-CoV-2 diagnosis

    by Leonardo Maia Leony, Larissa Carvalho Medrado Vasconcelos, Ricardo Sampaio Hein da Silva, Aquiles Assunção Camelier, Antônio Carlos Bandeira, Deivide Luis Souza Costa, Isadora Cristina de Siqueira, Fred Luciano Neves Santos


  • Open Access

    Comprehensive analysis of early T cell responses to acute Zika Virus infection during the first epidemic in Bahia, Brazil

    by Assia Samri, Antonio Carlos Bandeira, Luana Leandro Gois, Carlos Gustavo Regis Silva, Alice Rousseau, Aurelien Corneau, Nadine Tarantino, Christopher Maucourant, Gabriel Andrade Nonato Queiroz, Vincent Vieillard, et al.

    Background: In most cases, Zika virus (ZIKV) causes a self-limited acute illness in adults, characterized by mild clinical symptoms that resolve within a few days. Immune responses, both innate and adaptive, play a central role in controlling and eliminating virus-infected cells during the early stages of infection. Aim: To test the hypothesis that circulating T cells exhibit phenotypic and functional activation characteristics during the viremic phase of ZIKV infection. Methods: A comprehensive analysis using mass cytometry was performed on peripheral blood mononuclear cells obtained from patients with acute ZIKV infection (as confirmed by RT-PCR) and compared with that from healthy donors (HD). The frequency of IFN-γ-producing T cells in response to peptide pools covering immunogenic regions of structural and nonstructural ZIKV proteins was quantified using an ELISpot assay. Results: Circulating CD4+ and CD8+ T lymphocytes from ZIKV-infected patients expressed higher levels of IFN-γ and pSTAT-5, as well as cell surface markers associated with proliferation (Ki-67), activation ((HLA-DR, CD38) or exhaustion (PD1 and CTLA-4), compared to those from HD. Activation of CD4+ and CD8+ memory T cell subsets, including Transitional Memory T Cells (TTM), Effector Memory T cells (TEM), and Effector Memory T cells Re-expressing CD45RA (TEMRA), was prominent among CD4+ T cell subset of ZIKV-infected patients and was associated with increased levels of IFN-γ, pSTAT-5, Ki-67, CTLA-4, and PD1, as compared to HD. Additionally, approximately 30% of ZIKV-infected patients exhibited a T cell response primarily directed against the ZIKV NS5 protein. Conclusion: Circulating T lymphocytes spontaneously produce IFN-γ and express elevated levels of pSTAT-5 during the early phase of ZIKV infection whereas recognition of ZIKV antigen results in the generation of virus-specific IFN-γ-producing T cells.


  • Open Access

    Usefulness of receptor binding domain protein-based serodiagnosis of COVID-19

    by Larissa de Carvalho Medrado Vasconcelos, Leonardo Maia Leony, Aquiles Assunção Camelier, André Costa Meireles, André Luiz Freitas de Oliveira Júnior, Antônio Carlos Bandeira, Yasmin Santos Freitas Macedo, Alan Oliveira Duarte, Wesley Van Voorhis, Isadora Cristina de Siqueira, et al.


  • Open Access

    Prevalence and risk factors for long COVID after mild disease: A cohort study with a symptomatic control group

    by Ana B Cazé, Thiago Cerqueira-Silva, Adriele P Bomfim, Gisley L de Souza, Amanda Ca Azevedo, Michelle Qa Brasil, Nara R Santos, Ricardo Khouri, Jennifer Dan, Antonio C Bandeira, et al.

    Long COVID has received less attention from the scientific community than acute COVID-19, representing less than 2% of COVID-19 publications in PubMed Clinical Queries (as of August 31, 2022). Consequently, several important aspects remain undefined, such as its prevalence. Long COVID has been reported to affect between 7.5% to 89% of patients [1–4]. However, most […]


  • Open Access

    Genomic monitoring unveils a high prevalence of severe acute respiratory syndrome coronavirus 2 Omicron variant in vaccine breakthrough cases in Bahia, Brazil

    by Gúbio Soares Campos, Marta Giovanetti, Laíse de Moraes, Helena Souza da Hora, Antônio Carlos de Albuquerque Bandeira, Keila Veronica Oliveira Motta De Alcantara, Silvia Ines Sardi

    OBJECTIVE: Genome sequencing has been proved to be an excellent tool to monitor the molecular epidemiology of the disease caused by severe acute respiratory syndrome coronavirus 2, i.e., coronavirus disease 2019. Some reports of infected, vaccinated individuals have aroused great interest because they are primarily being infected with circulating variants of concern. To investigate the cases of infected, vaccinated individuals in Salvador, Bahia, Brazil, we performed genomic monitoring to estimate the magnitude of the different variants of concern in these cases.METHODS: Nasopharyngeal swabs from infected (symptomatic and asymptomatic), vaccinated or unvaccinated individuals (n=29), and quantitative reverse transcription polymerase chain reaction cycle threshold value (Ct values) of <= 30 were subjected to viral sequencing using nanopore technology.RESULTS: Our analysis revealed that the Omicron variant was found in 99% of cases and the Delta variant was found in only one case. Infected, fully vaccinated patients have a favorable clinical prognosis; however, within the community, they become viral carriers with the aggravating factor of viral dissemination of variants of concern not neutralized by the currently available vaccines.CONCLUSION: It is important to acknowledge the limitations of these vaccines and to develop new vaccines to emergent variants of concern, as is the case of influenza vaccine; going through new doses of the same coronavirus vaccines is "more of the same."